Renaissance Capital logo

AnPac Bio-Medical Science Scheduled, Nasdaq: ANPC

Chinese provider of multi-cancer screening tests.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a biotechnology company focusing on early cancer screening and detection. We market and sell a multi-cancer screening and detection test that uses our innovative, patented cancer differentiation analysis, or CDA, technology and our proprietary cancer-detection device, or CDA device. In addition to early cancer screening and detection, our CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence. Our CDA technology provides a comprehensive platform on which we have developed our cancer screening and detection test using our CDA technology, or CDA test, and our proprietary CDA device. Our CDA test can detect and assess an individual’s overall cancer risk with high accuracy, including early stage cancer. In addition, we also offer tests that combine our CDA test with auxiliary tests based on other cancer screening and detection technologies, such as biomarker-based tests, using our proprietary algorithm, which we refer to as combination tests. When we refer to our technology or tests as a “cancer screening and detection” technology or test in this prospectus, we refer to the detection and assessment of the risk of cancer occurrence, not to cancer diagnosis. Our CDA technology focuses on biophysical properties in human blood. Recent studies have shown that there is a correlation between certain biophysical properties, including acoustical, electrical, magnetic, nano-mechanical and optical properties, and cancer occurrence.
more less
IPO News for AnPac Bio-Medical Science
more
IPO Data
IPO File Date 10/31/2019
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 1.7
Deal Size ($mm) $22
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 1.7
Deal Size ($mm) $22
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Lishui, China
Founded 2010
Employees 101
Website www.anpacbio.com